Payment overview · 2025
General Payments
$170.55
18 reported records · 3 companies
Healthcare provider profile · identity verified
James M Caskey, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUFKIN, TX · NPI 1558371880
Verified facts
What the public records show
CMS Open Payments records show James M Caskey, MD received $170.55 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 80.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.99 | 80.3% | 16 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.43 | 11.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.13 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.55 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.24 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.56 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.75 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 76 |
| Losartan Potassium | Losartan Potassium | 200 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 53 |
| Lisinopril | Lisinopril | 184 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 52 |
| Metformin Hcl | Metformin Hcl | 156 | 49 |
| Gabapentin | Gabapentin | 155 | 45 |
| Omeprazole | Omeprazole | 153 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 43 |
| Furosemide | Furosemide | 134 | 42 |
| Alprazolam | Alprazolam | 132 | 37 |
| Simvastatin | Simvastatin | 131 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 31 |
| Trazodone Hcl | Trazodone Hcl | 100 | 34 |
| Azithromycin | Azithromycin | 98 | 77 |
| Finasteride | Finasteride | 95 | 21 |
| Meloxicam | Meloxicam | 95 | 41 |
| Ozempic | Semaglutide | 89 | 21 |
| Allopurinol | Allopurinol | 76 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 23 |
| Xarelto | Rivaroxaban | 74 | 11 |
| Eliquis | Apixaban | 72 | 14 |
| Montelukast Sodium | Montelukast Sodium | 70 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 17 |
| Tramadol Hcl | Tramadol Hcl | 69 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 20 |
| Jardiance | Empagliflozin | 63 | 16 |
| Estradiol | Estradiol | 55 | 17 |
| Spironolactone | Spironolactone | 54 | 16 |
| Mupirocin | Mupirocin | 51 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 22 |
| Celecoxib | Celecoxib | 47 | 14 |
| Pregabalin | Pregabalin | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 16 |
| Synthroid | Levothyroxine Sodium | 42 | 14 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 37 |
| Amoxicillin | Amoxicillin | 40 | 29 |
| Carvedilol | Carvedilol | 38 | 11 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Prednisone | Prednisone | 27 | 17 |
| Fluconazole | Fluconazole | 26 | 18 |
| Baclofen | Baclofen | 25 | 14 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 18 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | 12 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Cardura Xl | Doxazosin Mesylate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | 12 |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Evoxac | Cevimeline Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.55 · 18 records | ABBVIE INC. | BREZTRI, FREESTYLE LIBRE 3, QULIPTA, SYNTHROID, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error